Nefrología e hipertensión

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. Authorizaton to Use Clincially Obtained Data for Research

   Rochester, Minn.

   This study is being done to gather information regarding your health in relation to your composite tissue transplant. We would like to use your medical records (both existing and future) to study the health of patients who will receive or have received a composite tissue transplant. This research would include looking at your demographic information, cause of initial injury, laboratory test results and medical exams relating to your pre and post transplant care, and your mental well-being before and after transplant.

    

2. Post Approval Study For Treatment Of Drug-resistant Adult Primary FSGS Using The LIPOSORBER® LA-15 System

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult and pediatric patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient is post renal transplantation. Treatment for FSGS is considered unsuccessful if the patient is unresponsive to standard therapy (e.g., at least 8 weeks of corticosteroids) and fails to achieve complete or partial remission. A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit.

    

3. OBINUTUZUMAB in Treatment of Fibrillary Glomerulonephritis

   Rochester, Minn.

   The purpose of this study is to determine if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis.

4. Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits (PGNMID)

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with  monoclonal immunoglobulin deposits (PGNMID) by assessing improvement in proteinuria at 12 months.

   Additionally, to assess the safety of daratumumab SC in treating patients with PGNMID by assessing the incidence of major infections, eye complications, and cytopenias.

5. A Study of Genes that cause Cystic Kidney Disease

   Rochester, Minn.

   The overall objective of this study is to define genes causing cystic kidney disease and to determine the degree to which variants at these cystic kidney disease genes underlie the clinical diversity of these disorders. This will provide an insight into the disease mechanisms, and explore novel mutation screening methods.  A combination of mutation screening in clinically characterized human cystic kidney disease populations, gene hunting and exploration of incompletely penetrant alleles in humans will provide a comprehensive picture of how mutations cause the resulting phenotype.

6. Biobank Protocol, Rare Diseases Clinical Research Network

   Rochester, Minn.

   This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from their family members, for use in future research.

7. A Study to Form a Database of Children with Kidney Stone Disease

   Rochester, Minn.

   The purpose of this study is to establish a database to collect and analyze information on metabolic and environmental risk factors for kidney stone formation in children.

8. Obstructive Sleep Apnea Among Somali-Americans

   Rochester, Minn.

   The purpose of this study is to advance the understanding of obstructive sleep apnea as it relates to different ethnic origins as well as sex differences. The investigators will compare Somali patients with known obstructive sleep apnea (OSA) to individuals without OSA, and to individuals of other ethnic/racial origins to determine the risk factors (genetic and/or physiologic) associated with developing cardiovascular diseases. This will help the investigators to understand the unique sleep pathology of individuals of African descent.

9. Comparison Of In-Home Versus In-Clinic Administration Of Subcutaneous Nivolumab Through Cancer CARE (Connected Access And Remote Expertise) Beyond Walls (CCBW) Program

   Jacksonville, Fla.

   This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends and familiar surroundings for many hours per day. This separation adds to the physical, emotional, social, and financial burden for patients and their families. Traveling to and from medical facilities costs time, money, and effort and can be a disadvantage to patients living in rural areas, those with low incomes or poor access to transport. Studies have shown that cancer patients often feel more comfortable and secure being cared for in their own home environments. SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve the quality of life in cancer patients.

10. REstrictive versus LIberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury (RELIEVE-AKI)

    Rochester, Minn.

    The objective of this study is to evaluate the feasibility of alternative Net Ultrafiltration (UFNET) rate strategies among critically ill adults with acute kidney injury (AKI) and treated with Continuous Kidney Replacement Therapy (CKRT).

     

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. Authorizaton to Use Clincially Obtained Data for Research

   Rochester, Minn.

   This study is being done to gather information regarding your health in relation to your composite tissue transplant. We would like to use your medical records (both existing and future) to study the health of patients who will receive or have received a composite tissue transplant. This research would include looking at your demographic information, cause of initial injury, laboratory test results and medical exams relating to your pre and post transplant care, and your mental well-being before and after transplant.

    

2. Post Approval Study For Treatment Of Drug-resistant Adult Primary FSGS Using The LIPOSORBER® LA-15 System

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult and pediatric patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient is post renal transplantation. Treatment for FSGS is considered unsuccessful if the patient is unresponsive to standard therapy (e.g., at least 8 weeks of corticosteroids) and fails to achieve complete or partial remission. A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit.

    

3. OBINUTUZUMAB in Treatment of Fibrillary Glomerulonephritis

   Rochester, Minn.

   The purpose of this study is to determine if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis.

4. Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits (PGNMID)

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with  monoclonal immunoglobulin deposits (PGNMID) by assessing improvement in proteinuria at 12 months.

   Additionally, to assess the safety of daratumumab SC in treating patients with PGNMID by assessing the incidence of major infections, eye complications, and cytopenias.

5. A Study of Genes that cause Cystic Kidney Disease

   Rochester, Minn.

   The overall objective of this study is to define genes causing cystic kidney disease and to determine the degree to which variants at these cystic kidney disease genes underlie the clinical diversity of these disorders. This will provide an insight into the disease mechanisms, and explore novel mutation screening methods.  A combination of mutation screening in clinically characterized human cystic kidney disease populations, gene hunting and exploration of incompletely penetrant alleles in humans will provide a comprehensive picture of how mutations cause the resulting phenotype.

6. Biobank Protocol, Rare Diseases Clinical Research Network

   Rochester, Minn.

   This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from their family members, for use in future research.

7. A Study to Form a Database of Children with Kidney Stone Disease

   Rochester, Minn.

   The purpose of this study is to establish a database to collect and analyze information on metabolic and environmental risk factors for kidney stone formation in children.

8. Obstructive Sleep Apnea Among Somali-Americans

   Rochester, Minn.

   The purpose of this study is to advance the understanding of obstructive sleep apnea as it relates to different ethnic origins as well as sex differences. The investigators will compare Somali patients with known obstructive sleep apnea (OSA) to individuals without OSA, and to individuals of other ethnic/racial origins to determine the risk factors (genetic and/or physiologic) associated with developing cardiovascular diseases. This will help the investigators to understand the unique sleep pathology of individuals of African descent.

9. Comparison Of In-Home Versus In-Clinic Administration Of Subcutaneous Nivolumab Through Cancer CARE (Connected Access And Remote Expertise) Beyond Walls (CCBW) Program

   Jacksonville, Fla.

   This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends and familiar surroundings for many hours per day. This separation adds to the physical, emotional, social, and financial burden for patients and their families. Traveling to and from medical facilities costs time, money, and effort and can be a disadvantage to patients living in rural areas, those with low incomes or poor access to transport. Studies have shown that cancer patients often feel more comfortable and secure being cared for in their own home environments. SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve the quality of life in cancer patients.

10. REstrictive versus LIberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury (RELIEVE-AKI)

    Rochester, Minn.

    The objective of this study is to evaluate the feasibility of alternative Net Ultrafiltration (UFNET) rate strategies among critically ill adults with acute kidney injury (AKI) and treated with Continuous Kidney Replacement Therapy (CKRT).